News summary

Biolexis advances oral obesity drug after Phase 1a results

Source: Longevity Technology • Published: 16 Nov 2026, 11:41

Summarized by Masters of Longevity from Longevity Technology.

Biolexis reported first-in-human Phase 1a data for BLX-7006 and will present the results.

Biolexis advances oral obesity drug after Phase 1a results
Key Takeaways
  • Phase 1a tested BLX-7006 in healthy human volunteers.
  • Company will present data at ObesityWeek 2026 conference.
  • These early results are exploratory and not efficacy proof.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.